NCT04948554

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.

Conditions

• Systemic Sclerosis With and Without Interstitial Lung Disease

Interventions

Type	Name	Description
BIOLOGICAL	MK-2225	Administered Subcutaneously (SC)
BIOLOGICAL	Placebo	Administered SC

Timeline

• Start date: 2023-03-10
• Primary completion: 2023-10-18
• Completion: 2023-10-18
• First posted: 2021-07-02
• Last updated: 2023-11-24

Locations

16 sites across 4 countries: United States, Canada, Italy, Switzerland

Regulatory

• FDA-regulated drug study